Massive mpox vaccine trial launches in DRC to protect thousands
NCT ID NCT07093489
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 35 times
Summary
This study will test the LC16m8 mpox vaccine in nearly 12,000 people aged 1 year and older in the Democratic Republic of Congo. The goal is to see if the vaccine is safe and provides strong protection against mpox. Participants will receive the vaccine and be monitored for side effects and infection rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MPOX are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Institut National de la Recherche Biomédicale (INRB)
Kinshasa, Democratic Republic of the Congo
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.